
    
      OBJECTIVES:

        -  Determine the response rate of patients with relapsed or recurrent advanced mycosis
           fungoides or SÃ©zary syndrome treated with alemtuzumab.

        -  Determine the toxicity of this drug in these patients.

      OUTLINE: Patients receive alemtuzumab IV over 2 hours three times per week. Treatment
      continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity.

      Patients are followed every 3 months.

      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 2 years.
    
  